The DOI matches its Crossref record.
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Open accessAbstract
What is already known about this subject • Rivaroxaban is a novel anticoagulant with predictable, dose‐proportional pharmacokinetics and pharmacodynamics in healthy subjects. • It is in clinical development for the prevention of thromboembolic disorders in patients undergoing major orthopaedic surgery. • Nonsteroidal anti‐inflammatory drugs (NSAIDs), such as naproxen, are widely used for pain relief and treatment of inflammation, particularly in patients who have undergone orthopaedic surgery. As it is likely that patients receiving rivaroxaban after orthopaedic surgery will also receive NSAIDs, this study was performed to determine whether there was any mechanistic interaction between rivaroxaban and naproxen. What this study adds • This study demonstrated that there was no mechanistic interaction between rivaroxaban and naproxen in healthy subjects. • This finding was used to design large‐scale clinical trials of rivaroxaban, in which patients were also allowed to use NSAIDs. • These ongoing trials will provide definitive data regarding the interaction between rivaroxaban and NSAIDs. Aims: Rivaroxaban (BAY 59‐7939) is in advanced clinical development for the prevention and treatment of thromboembolic disorders. Frequent co‐medications in the patient populations likely to receive rivaroxaban include NSAIDs. This randomized, two‐way crossover study, with a naproxen run‐in period, was performed to determine whether naproxen influences the tolerability, pharmacodynamics and pharmacokinetics of rivaroxaban. Methods: Eleven healthy, young males received naproxen 500 mg on two consecutive days, a single dose of rivaroxaban 15 mg, or both. Results: Treatments were well tolerated: adverse events (eight in total), reported by three subjects, were mild and not drug related. Rivaroxaban inhibited Factor Xa activity by 35% and prolonged prothrombin time [by 1.4 times baseline (tb)], activated partial thromboplastin time (1.3 tb) and the HepTest (1.9 tb). Naproxen had no influence on these measures and the combination of rivaroxaban and naproxen did not affect platelet aggregation. Rivaroxaban and naproxen given together significantly increased bleeding time compared with rivaroxaban alone (P = 0.017). However, this difference was small compared with the effect of naproxen given alone, except in one subject. Least squares‐means ratios for the AUC and Cmax of rivaroxaban after administration alone and with naproxen were 1.125 [90% confidence interval (CI) 0.995, 1.271] and 1.095 (90% CI 0.905, 1.325), respectively. Conclusions: There appeared to be no clinically relevant interaction between rivaroxaban and naproxen in healthy subjects, although some individuals may be more sensitive to the combination. Large‐scale Phase III clinical studies will be required to confirm whether there is an increased risk of bleeding during treatment with rivaroxaban and concomitant NSAIDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Self-citationEriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Metadata
- Authors
- Kubitza, D., Becka, M., Mueck, W., & Zuehlsdorf, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2006-11-13
- Volume
- 63
- Issue
- 4
- Pages
- 469-476
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2123448465
- Cited by
- 158
- References
- 0
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. https://app.cochat.ai/papers/10.1111/j.1365-2125.2006.02776.x
- The paper
- Kubitza, D., Becka, M., Mueck, W., & Zuehlsdorf, M. (2007). Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2006.02776.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.